{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VEGF&page=15", "query": { "condition": "VEGF", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 426, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VEGF&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=VEGF&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T04:56:43.436Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00941499", "title": "Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "HAI Oxaliplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 140, "start_date": "2009-07", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941499" }, { "nct_id": "NCT04125732", "title": "Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Coronary Artery Disease", "Ischemia", "Angina Refractory", "Cardiovascular Diseases", "Heart Diseases" ], "interventions": [ { "name": "AdVEGFXC1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "XyloCor Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 41, "start_date": "2020-01-24", "completion_date": "2023-05-30", "has_results": false, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 16, "location_summary": "Stanford, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 11 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04125732" }, { "nct_id": "NCT01391962", "title": "Sunitinib or Cediranib for Alveolar Soft Part Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma, Alveolar Soft Part" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Prochlorperazine", "type": "OTHER" }, { "name": "Promethazine", "type": "OTHER" }, { "name": "Benzodiazepine", "type": "OTHER" }, { "name": "Filgrastim", "type": "OTHER" }, { "name": "Sargramostim", "type": "OTHER" }, { "name": "Lomotil", "type": "OTHER" }, { "name": "Loperamide", "type": "OTHER" }, { "name": "Vitamin B6", "type": "OTHER" }, { "name": "Aquaphor", "type": "OTHER" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Levothyroxine", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "16 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2011-07-18", "completion_date": "2026-01-16", "has_results": true, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391962" }, { "nct_id": "NCT00444535", "title": "Lapatinib and Bevacizumab for Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 52, "start_date": "2007-02-27", "completion_date": "2020-06-19", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 9, "location_summary": "Tucson, Arizona • San Francisco, California • Hollywood, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Basking Ridge", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00444535" }, { "nct_id": "NCT04707625", "title": "Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Retinal Vein Occlusion" ], "interventions": [ { "name": "Aflibercept Ophthalmic", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-10-06", "completion_date": "2023-12-18", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04707625" }, { "nct_id": "NCT07224776", "title": "Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Proteinuric Renal Disease", "Proteinuric Kidney Disease", "Proteinuria", "Proteinuria in Nephrotic Range" ], "interventions": [ { "name": "sparsentan", "type": "DRUG" }, { "name": "No sparsentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-07-10", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224776" }, { "nct_id": "NCT01674569", "title": "Pilot Study of X-82 in Patients With Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Exudative Macular Degeneration" ], "interventions": [ { "name": "X-82 oral", "type": "DRUG" }, { "name": "ranibizumab (Lucentis)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyrogenex", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 35, "start_date": "2012-10", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 5, "location_summary": "Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "New London", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Abilene", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674569" }, { "nct_id": "NCT04051957", "title": "Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Injury", "Proteinuria", "Hypertension" ], "interventions": [ { "name": "Isosorbide Mononitrate", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 9, "start_date": "2019-09-26", "completion_date": "2021-02-12", "has_results": true, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04051957" }, { "nct_id": "NCT07503613", "title": "Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Vestibular Schwannoma" ], "interventions": [], "intervention_types": [], "sponsor": "Akouos, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-03-02", "completion_date": "2040-04", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07503613" }, { "nct_id": "NCT00667342", "title": "A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma", "Malignant Fibrous Histiocytoma (MFH) of Bone" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 43, "start_date": "2008-06-03", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-11-02T04:56:43.436Z", "location_count": 5, "location_summary": "San Diego, California • Baltimore, Maryland • Bethesda, Maryland + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667342" } ] }